Practical Recommendations of Scientific Society for the Study of Human Microbiome and Russian Gastroenterological Association (RGA) for Probiotics in Treatment and Prevention of Gastroenterological Diseases in Adults

Ивашкин, В. Т.; Маев, И. В.; Абдулганиева, Д. И.; Алексеенко, С. А.; Ивашкина, Н. Ю.; Корочанская, Н. В.; Маммаев, С. Н.; Poluektova, Elena; Трухманов, А. С.; Успенский, Ю. П.; Цуканов, В. В.; Шифрин, О. С.; Зольникова, О. Ю.; Ивашкин, К. В.; Лапина, Т. Л.; Maslennikov, Roman; Ульянин, А. И.

doi:10.22416/1382-4376-2020-30-2-76-89

Cited by 17 publications

(12 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Результаты некоторых исследований демонстрируют, что пробиотики и пребиотики могут способствовать нормализации липидного профиля (снижение уровня общего холестерина (ОХ) и холестерина липопротеинов низкой плотности (ЛПНП), триглицеридов, увеличение холестерина липопротеинов высокой плотности (ЛПВП)), оказывая тем самым терапевтическое и профилактическое влияние на течение сердечно-сосудистых заболеваний [44]. Пробиотики (L. lactis, Bifidobacterium) секретируют аналог инсулина с характерным биологическим эффектом и могут применяться при лечении сахарного диабета второго типа [44,45]. Обсуждается также возможность применения пробиотиков при ВИЧ-инфекции [46].…”

Section: пробиотики и пребиотикиunclassified

“…В качестве пребиотиков используются фруктоолигосахариды, галактоолигосахариды, лактулоза и неперевариваемые полисахариды (инулин, целлюлоза, гемицеллюлоза, пектины и пр.) [20,44]. Большинство пребиотиков, включая фруктоолигосахариды и инулин, перевариваются бифидобактериями, что способствует стимулированию их роста [44].…”

Section: пробиотики и пребиотикиunclassified

“…[20,44]. Большинство пребиотиков, включая фруктоолигосахариды и инулин, перевариваются бифидобактериями, что способствует стимулированию их роста [44]. Пребиотики естественным образом присутствуют в овощах, таких как артишоки, лук, цикорий, чеснок и лук-порей.…”

Section: пробиотики и пребиотикиunclassified

“…Напротив, синбиотик не оказал благоприятного воздействия на индекс массы тела (ИМТ), окружность талии и уровни холестерина ЛПВП [60]. Необходимо отметить, что результаты проведенных к настоящему времени исследований про-и пребиотиков гетерогенны и эффект от их применения часто зависит от тестируемых штаммов пробиотиков [44].…”

Section: пробиотики и пребиотикиunclassified

See 3 more Smart Citations

Modern approaches to the correction of the gut microbiota

2021

View full text Add to dashboard Cite

The article presents modern data on the formation, structure, functions and possibilities of correction of the gut microbiota. The gut microbiota is a collection of living organisms that inhabit the human intestine and form a complex microecological system that performs many functions. It is known that the composition and state of the gut microbiota is influenced by both environmental factors, such as diet and lifestyle, and the human body, including genetic predisposition. A violation in this system (dysbiosis) can provoke the development of a number of diseases and pathological conditions, in which the correction of the gut microbiota may be a promising therapeutic strategy. The most common methods of correcting dysbiosis are dieting, the use of pro-and prebiotics, and fecal microbiota transplantation. The diet affects the qualitative and quantitative composition and functions of the gut microbiota, the activity of its individual representatives. Probiotics are used to modulate, preserve the gut microbiota in dysbiosis, as well as to prevent its development. Fecal microbiota transplantation is performed by transferring the microbiota from a healthy donor. This method is one of the most effective ways to treat Clostridium difficile infection. This review article also presents the results of fecal microbiota transplantation in patients with inflammatory bowel disease and hepatic encephalopathy. It is shown that after transplantation, there is a rapid change in the composition of the gut microbiota, which becomes similar to the microbiota of a healthy donor. Each of these methods of correction demonstrates a different degree of influence on the gut microbiota, and their therapeutic effectiveness depends on the direct characteristics of the methods used, as well as the specific disease and requires further study.

show abstract

Section: пробиотики и пребиотикиunclassified

See 2 more Smart Citations

Modern approaches to the correction of the gut microbiota

2021

View full text Add to dashboard Cite

show abstract

“…Включение пробиотика, как предполагается, уменьшает вероятность нежелательных явлений на фоне приема антибактериальных препаратов, что, свою очередь, способствует повышению приверженности пациента лечению и проведению полного курса эрадикационной терапии. Вместе с тем в качестве возможных средств, повышающих эффективность эрадикационной терапии, рекомендуется прием лишь определенных пробиотиков [36]. Помимо этого, последние рекомендации РГА допускают использование цитопротектора -ребамипида при применении тройной терапии для повышения уровня эрадикации микроорганизма [37,38].…”

Section: ðèñ 4 ñõåìû ýðàäèêàöèîííîé òåðàïèè íàçíà÷åííûå â êà÷åñòâåunclassified

European Registry on the management of Helicobacter pylori infection: features of diagnosis and treatment in Kazan

Абдулхаков

Bordin

Абдулхаков³

et al. 2020

Terapevticheskii arkhiv

View full text Add to dashboard Cite

Background. As part of an observational multicenter prospective study European Registry on the management of Helicobacter pylori infection, conducted on the initiative of the European H. pylori and Microbiota Study Group, the compliance of clinical practice in the management of patients with Helicobacter pylori infection in Kazan with clinical guidelines was assessed. Materials and methods. The data of 437 patients included into the register by clinical sites in Kazan in 20132019 were analyzed. The methods used for the initial diagnosis of H. pylori infection and eradication control were evaluated. The frequency of various eradication therapy regimens prescription was analyzed in 379 cases. Data regarding the effectiveness of eradication therapy was analyzed in 173 patients. Results. The rapid urease test (44.2% of cases) and cytology/histology (60% of cases) were most often used for the initial diagnosis of H. pylori infection; however non-invasive methods such as 13C-urea breath (9.2%), serology (6.2%), H. pylori stool antigen test (2.3%) were less common. In 21.7% of patients two methods of H. pylori detection were used for primary diagnosis. The control test to evaluate the effectiveness of eradication therapy at the recommended timepoint was performed in 46.2% of patients. 13C-urea breath test (31.7%), stool PCR/stool antigen test (28.7%), rapid urease test (22.3%), cytology/histology (26.2% of cases) prevailed in the assessment of eradication rate. Standard triple therapy, including proton pump inhibitor, clarithromycin and amoxicillin was most commonly prescribed as first-line therapy (64.6% of cases). The duration of eradication therapy was 14 days in the majority of cases with pantoprazole as the most common proton pump inhibitor in standard triple therapy regimens (84.8%). The efficacy of 14-day standard triple therapy (mITT) was 87.0%. Conclusion. The results indicate a high frequency of non-invasive methods use for assessing the effectiveness of eradication therapy; however, the overall rate of eradication efficacy assessment is low, limiting the possibility of analyzing the eradication results. The effectiveness of the most common 14-day standard triple first-line therapy in Kazan doesnt reach the recommended 90% eradication level. This could be explained by high rate of pantoprazole use, which is not an optimal proton pump inhibitor in eradication therapy regimens.

show abstract

Microbiota and Cardiovascular Diseases: Mechanisms of Influence and Correction Possibilities

Gorbenko

Skirdenko

Andreev

et al. 2023

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

The term "microbiota" refers to the microbial community occupying a specific habitat with defined physical and chemical properties and forming specific ecological niches. The adult intestinal microbiota is diverse. It mainly consists of bacteria of Bacteroidetes and Firmicutes types. The link between the gut microbiota and cardiovascular disease (CVD) is being actively discussed. Rapid progress in this field is explained by the development of new generation sequencing methods and the use of sterile gut mice in experiments. More and more data are being published about the influence of microbiota on the development and course of hypertension, coronary heart disease (IHD), myocardial hypertrophy, chronic heart failure (CHF) and atrial fibrillation (AF). Diet therapy, antibacterial drugs, pro- and prebiotics are successfully used as tools to correct the structure of the gut microbiota of the macroorganism. Correction of gut microbiota in an experiment on rats with coronary occlusion demonstrates a significant reduction in necrotic area. A study involving patients suffering from CHF reveals a significant reduction in the level of uric acid, highly sensitive C-reactive protein, and creatinine. In addition to structural and laboratory changes in patients with CVD when modifying the microbiota of the gut, also revealed the effect on the course of arterial hypertension. Correction of gut microbiota has a beneficial effect on the course of AF. We assume that further active study of issues of influence and interaction of gut microbiota and macroorganism may in the foreseeable future make significant adjustments in approaches to treatment of such patients.

show abstract

Practical Recommendations of Scientific Society for the Study of Human Microbiome and Russian Gastroenterological Association (RGA) for Probiotics in Treatment and Prevention of Gastroenterological Diseases in Adults

Cited by 17 publications

References 30 publications

Modern approaches to the correction of the gut microbiota

Modern approaches to the correction of the gut microbiota

European Registry on the management of Helicobacter pylori infection: features of diagnosis and treatment in Kazan

Microbiota and Cardiovascular Diseases: Mechanisms of Influence and Correction Possibilities

Contact Info

Product

Resources

About